Sarepta Stock Surges: FDA's Viral Vector Breakthrough!

Sarepta Therapeutics, Inc. rose 3.01% intraday, with the company receiving FDA platform technology designation for its viral vector rAAVrh74 used in the investigational gene therapy SRP-9003 for the treatment of limb-girdle muscular dystrophy type 2E/R4. This designation underscores the reproducibility and adaptability of the technology across multiple therapeutic programs, reinforcing Sarepta's leadership in precision genetic medicine for rare diseases.